We are pleased to announce that the acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners has been completed. Read the Press Release
Download PDF Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geographic reach […]
Read moreDownload PDFAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development […]
Read moreDownload PDFTUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction […]
Read moreDownload PDFTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) today announced they have entered into a definitive […]
Read moreDownload PDFTUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, […]
Read moreDownload PDFTUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers […]
Read more© 2025 Avid Bioservices, Inc. All rights reserved.
